Skip to main content
. 2017 Apr;361(1):99–108. doi: 10.1124/jpet.116.239459

Fig. 6.

Fig. 6.

Total CF, NOS-dependent CF, and cGMP levels in luteolinidin-treated and untreated hearts. (A) After 30-minute reperfusion, total CF was significantly higher in hearts treated preischemia with 15, 25, and 50 μM luteolinidin compared with hearts receiving vehicle treatment (I/R). (B) NOS-dependent CF was also higher in hearts pretreated with 15, 25, and 50 μM luteolinidin. Luteolinidin preserved eNOS functionality, as much higher recovery of NOS-dependent CF was seen in hearts treated with luteolinidin. (C) Consistent with higher NOS-dependent CF, cGMP levels after stimulation with 1 μM acetylcholine were higher in luteolinidin-treated hearts (50 μM) compared with vehicle-treated I/R (I/R), which showed significant impairment of acetylcholine-induced cGMP production. For (A) and (B), *P < 0.05; **P < 0.01; ***P < 0.001 (with respect to I/R; mean ± S.E.M., n = 6–10). For (C), **P < 0.01; †P < 0.01 (with respect to control and I/R, respectively; mean ± S.E.M., n = 7).